Suche klinische Studie
Weitere Suchoptionen
46 Ergebnis(se)
Rekrutierende Studie = ; Fortlaufende Studie =
; Förderung durch ein IRDiRC-Mitglied =
; ERN-Mitglied =
Nationale klinische Studie(n)

VLAAMS BRABANT
LEUVEN

Do Peri-operative High Doses of Intravenous Glucocorticoids Improve Short-term Functional Outcome After Direct Anterior Total Hip Arthroplasty? A Randomized, Single Surgeon, Placebo Controlled, Double Blind Study
UZ Leuven - Campus Gasthuisberg
Orthopedie

ANTWERPEN
EDEGEM (ANTWERPEN)

STAND: A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea / Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises - BE
University Hospital Antwerp - UZA
Oncologie en hematologie kinderen

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occlusive Crisis - BE
Hôpital Universitaire des Enfants Reine Fabiola - HUDERF
Service d'hémato-oncologie, d'immunologie et de rhumatologie pédiatrique

South-West region
SOFIA

ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - BG -
University Hospital Alexandrovska
Clinic of Hematology

Berlin
ADDRESS: NOT PROVIDED - DE

Eine Phase-3-Studie zur Evaluierung der Gentherapie durch Transplantation von autologen CD34+-Stammzellen, die ex vivo mit dem LentiGlobin BB305 Lentivirus-Vektor transduziert wurden, bei Patienten mit Sichelzellanämie
Institution: Information not provided - DE

Berlin
ADDRESS: NOT PROVIDED - DE
Eine multizentrische, offene Phase-2-Studie zur Beurteilung der angemessenen Dosierung und zur Bewertung der Sicherheit von Crizanlizumab mit oder ohne Hydroxyharnstoff/Hydroxycarbamid in aufeinanderfolgenden, absteigenden Altersgruppen von pädiatrischen Patienten mit Sichelzellkrankheit und vasookklusiver Krise
Institution: Information not provided - DE

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

VERSATIS : Efficacy and safety of lidocaine 5% patches (Versatis ® 5%) in neuropathic pain and sickle cell vaso-occlusive crises pain in children, adolescents and young adults - FR
Institution: Information not provided - FR

ILE-DE-FRANCE
CLICHY

ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - FR -
CHU Paris Nord-Val de Seine - Hôpital Beaujon
Service de médecine interne

ILE-DE-FRANCE
PARIS

DREP-HAPLO : Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease (Phase II)
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service d'Hématologie - Unité Adolescents et Jeunes Adultes (AJA)

ILE-DE-FRANCE
PARIS

DRO2G : Impact of Home-based Oxygen Therapy on Maternal and Fetal Complications, in Pregnant Women With Sickle Cell Disease. A Randomized Multi-center Trial (Phase III)
Hôpital Necker-Enfants Malades
Département de Biothérapie - Unité d'Hémaphérèse Thérapeutique

ISRAEL
PETAH TIKVA

ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - IL -
Rabin Medical Center - Beilinson Hospital
Recanati Genetic Institute

FRIULI VENEZIA GIULIA
UDINE

ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - IT -
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Centro di Coordinamento Regionale per le Malattie Rare

LIGURIA
GENOVA


A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602) - IT
Ospedali Galliera
S.S.D. Ematologia

Beyrouth
BEIRUT

ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - LB -
Hôtel-Dieu de France, Université Saint-Joseph
Oncology & Hematology

Noord-Holland
AMSTERDAM
Microvascular Damage in Sickle Cell Disease
Amsterdam UMC, locatie AMC
Afdeling Hematologie

Suisse Romande
ADDRESS: NOT PROVIDED - CH
A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occlusive Crisis - CH
Institution: Information not provided - CH

Madrid
ADDRESS: NOT PROVIDED - ES


ELIKIDS: Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3 - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occlusive Crisis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

STAND: A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea / Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
STEADFAST: A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients >= 16 years with chronic kidney disease due to sickle cell nephropathy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

HIBISCUS. An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

An Open-label, Multi-center, Phase IV, Rollover Study for Patients with Sickle Cell Disease who have Completed a Prior Novartis-Sponsored Crizanlizumab Study - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


CROSSWALK-c: A randomized double-blind phase IIa study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab as adjunct treatment in prevention of vaso-occlusive episodes (VOE) in sickle cell disease (SCD) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


CROSSWALK-a: A phase Ib randomized, placebo-controlled study evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy of crovalimab for the management of acute uncomplicated vaso-occlusive episodes (VOE) in patients with sickle cell disease (SCD) - ES
Institution: Information not provided - ES

Capital City Prague
PRAHA

ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - CZ -
Vseobecna fakultni nemocnice a 1. lekarska fakulta UK
National Centre for Treatment of Gaucher Disease

TUNISIA
TUNIS

ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - TN -
Hôpital La Rabta
Service de Pédiatrie

TURKEY
IZMIR

ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - TR -
Ege Üniversitesi
Department of Pediatrics - Cocuk asgligi ve Hastaliklari Anabilim Dali

Georgia
ATLANTA


Phase 2 Randomized Control Trial of Arginine Therapy for Pediatric Sickle Cell Disease Pain - US
Emory University

Massachusetts
CAMBRIDGE

New York
NEW YORK


Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain - US
Albert Einstein College of Medicine

New York
NEW YORK


High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device) - US
Columbia University

New York
NEW YORK

Vitamin D for Sickle-cell Respiratory Complications (Phase II) - US
Columbia University

Tennessee
NASHVILLE

Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (Also Known as the Montelukast Trial in Sickle Cell Anemia) (Phase II) - US
Vanderbilt University

Texas
DALLAS


LEAP: A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 (Phase II) - US
Baylor University Medical Center
Institute of Metabolic Disease

WIEN
ADDRESS: NOT PROVIDED - AT
ALIFE2: Anticoagulants for living fetuses for women with recurrent miscarriage and inherited blood clotting disorders (phase 3) - AT
Institution: Information not provided - AT

WIEN
WIEN

A Multicentre, Prospective, Open-label, Uncontrolled Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
Multinationale klinische Studie(n)

Noord-Holland
NAARDEN

Utrecht
ADDRESS: NOT PROVIDED - NL
EDGE: A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with Gaucher Disease Type 1 who have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Institution: Information not provided - NL

Utrecht
WOERDEN
Oral Miglustat in Adult patients With Stable Type 1 Gaucher Disease (Phase III) (coordination)
Actelion Pharmaceuticals Nederland B.V.

Region Stockholm
SÖDERTALJE

Suisse Alémanique
ALLSCHWIL
Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH) (Phase III) (coordination)
Actelion Pharmaceuticals Ltd.

California
SOUTH SAN FRANCISCO
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease
Global Blood Therapeutics

California
SOUTH SAN FRANCISCO
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
Global Blood Therapeutics

Massachusetts
CAMBRIDGE

Massachusetts
CAMBRIDGE

Washington
ADDRESS: NOT PROVIDED - US